Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT05186974. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT05186974
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 193 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab Govitecan-hziy (SG) Drug
- Pembrolizumab Drug
- Carboplatin Drug
- Cisplatin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2022 (Actual)
- Primary completion
- Mar 2027 (Estimated)
- Completion
- Mar 2027 (Estimated)
- Last update posted
- Sep 11, 2026
2022 – 2027
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology and Hematology, LLC. | Anchorage | Alaska | 99508 | — |
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| UCLA Hematology/Oncology - Santa Monica | Los Angeles | California | 90404 | — |
| UC Irvine Health | Orange | California | 92868 | — |
| Stanford Cancer Institute | Stanford | California | 94305 | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) | Aurora | Colorado | 80045 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northside Hospital Central Research Department | Atlanta | Georgia | 30342 | — |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Orchard Healthcare Research Inc. | Skokie | Illinois | 60077 | — |
| Kansas City Veterans Affairs Medical Center | Westwood | Kansas | 66205 | — |
| Kansas City VA Medical Center | Kansas City | Missouri | 64128 | — |
| Weill Cornell Medical/New York-Presbyterian Hospital | New York | New York | 10065 | — |
| Great Lakes Cancer Care | Williamsville | New York | 14226 | — |
| Wake Forest Baptist Health - High Point Medical Center | High Point | North Carolina | 27262 | — |
| FirstHealth Outpatient Cancer Center | Pinehurst | North Carolina | 28374 | — |
| University Hospital Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| OSU Brain & Spine Hospital | Columbus | Ohio | 43220 | — |
| Siouxland Regional Cancer Center dba June E. Nylen Cancer Center | North Sioux City | South Dakota | 51101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05186974, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2026 · Synced Nov 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05186974 live on ClinicalTrials.gov.